<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>dbdataset • dbdataset</title>
<!-- jquery --><script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script><!-- Bootstrap --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.4.1/css/bootstrap.min.css" integrity="sha256-bZLfwXAP04zRMK2BjiO8iu9pf4FbLqX6zitd+tIvLhE=" crossorigin="anonymous">
<script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.4.1/js/bootstrap.min.js" integrity="sha256-nuL8/2cJ5NDSSwnKD8VqreErSWHtnEP9E7AySL+1ev4=" crossorigin="anonymous"></script><!-- bootstrap-toc --><link rel="stylesheet" href="../bootstrap-toc.css">
<script src="../bootstrap-toc.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous">
<!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- pkgdown --><link href="../pkgdown.css" rel="stylesheet">
<script src="../pkgdown.js"></script><meta property="og:title" content="dbdataset">
<meta property="og:description" content="dbdataset">
<!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]-->
</head>
<body data-spy="scroll" data-target="#toc">
    <div class="container template-article">
      <header><div class="navbar navbar-default navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <span class="navbar-brand">
        <a class="navbar-link" href="../index.html">dbdataset</a>
        <span class="version label label-default" data-toggle="tooltip" data-placement="bottom" title="Released version">5.1.6</span>
      </span>
    </div>

    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
<li>
  <a href="../index.html">
    <span class="fas fa fas fa-home fa-lg"></span>
     
  </a>
</li>
<li>
  <a href="../articles/dbdataset.html">Get started</a>
</li>
<li>
  <a href="../reference/index.html">Reference</a>
</li>
      </ul>
<ul class="nav navbar-nav navbar-right">
<li>
  <a href="https://github.com/Dainanahan/dbdataset/">
    <span class="fab fa fab fa-github fa-lg"></span>
     
  </a>
</li>
      </ul>
</div>
<!--/.nav-collapse -->
  </div>
<!--/.container -->
</div>
<!--/.navbar -->

      

      </header><script src="dbdataset_files/htmlwidgets-1.5.1/htmlwidgets.js"></script><script src="dbdataset_files/jquery-1.12.4/jquery.min.js"></script><link href="dbdataset_files/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet">
<script src="dbdataset_files/datatables-binding-0.13/datatables.js"></script><link href="dbdataset_files/dt-core-1.10.20/css/jquery.dataTables.min.css" rel="stylesheet">
<link href="dbdataset_files/dt-core-1.10.20/css/jquery.dataTables.extra.css" rel="stylesheet">
<script src="dbdataset_files/dt-core-1.10.20/js/jquery.dataTables.min.js"></script><link href="dbdataset_files/crosstalk-1.1.0.1/css/crosstalk.css" rel="stylesheet">
<script src="dbdataset_files/crosstalk-1.1.0.1/js/crosstalk.min.js"></script><script src="dbdataset_files/d3-4.5.0/d3.min.js"></script><script src="dbdataset_files/radialNetwork-binding-0.4/radialNetwork.js"></script><div class="row">
  <div class="col-md-9 contents">
    <div class="page-header toc-ignore">
      <h1 data-toc-skip>dbdataset</h1>
            
      
      <small class="dont-index">Source: <a href="https://github.com/Dainanahan/dbdataset/blob/master/vignettes/dbdataset.Rmd"><code>vignettes/dbdataset.Rmd</code></a></small>
      <div class="hidden name"><code>dbdataset.Rmd</code></div>

    </div>

    
    
<div id="overview" class="section level2">
<h2 class="hasAnchor">
<a href="#overview" class="anchor"></a>Overview</h2>
<p><strong>dbdataset</strong> is a data package containing 75 different data frames that constitute the dataset parsed from <a href="https://www.drugbank.ca">DrugBank</a>. The dataset was extracted from the DrugBank XML database via <a href="https://dainanahan.github.io/dbparser/">dbparser</a> R package.</p>
<p>The dataset can be used for conveniently exploring and analyzing the contents of the DrugBank database. The dataset is also intended to assist in drug discovery endeavors that plan to make use of the <strong>DrugBank</strong> database.</p>
<p>Moreover; it also can be used to in Machine Learning in many sub-fields such as:</p>
<ul>
<li>Natural Language Processing (NLP)</li>
<li>Web Scrapping</li>
<li>Visualization</li>
</ul>
<div id="installation" class="section level3">
<h3 class="hasAnchor">
<a href="#installation" class="anchor"></a>Installation</h3>
<p>As the package size exceeds the limit set by CRAN, it will be hosted on Github only for now. Hence, it could be installed via the following command.</p>
<div class="sourceCode" id="cb1"><html><body><pre class="r"><span class="kw pkg">devtools</span><span class="kw ns">::</span><span class="fu"><a href="https://devtools.r-lib.org//reference/remote-reexports.html">install_github</a></span>(<span class="st">"Dainanahan/dbdataset"</span>)</pre></body></html></div>
<p>The datasets will then be available after running the following command:</p>
<div class="sourceCode" id="cb2"><html><body><pre class="r"><span class="fu"><a href="https://rdrr.io/r/base/library.html">library</a></span>(<span class="no">dbdataset</span>)</pre></body></html></div>
<p>Then the pakages will be available to be used as regular <em>R</em> object</p>
<div class="sourceCode" id="cb3"><html><body><pre class="r"><span class="fu"><a href="https://rdrr.io/r/utils/head.html">head</a></span>(<span class="kw pkg">dbdataset</span><span class="kw ns">::</span><span class="no">Articles_Drug</span>)
<span class="co">#&gt;   ref-id pubmed-id</span>
<span class="co">#&gt; 1     A1  16244762</span>
<span class="co">#&gt; 2     A2  16690967</span>
<span class="co">#&gt; 3     A3  16241940</span>
<span class="co">#&gt; 4     A4  10480573</span>
<span class="co">#&gt; 5     A5  10601294</span>
<span class="co">#&gt; 6     A6  10628369</span>
<span class="co">#&gt;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       citation</span>
<span class="co">#&gt; 1                                                                                                                                                                                                                                                                                                                                                                            Smythe MA, Stephens JL, Koerber JM, Mattson JC: A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost. 2005 Oct;11(4):371-4.</span>
<span class="co">#&gt; 2 Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, Gruel Y, Wolf M, Francois D, Racadot E, Camarasa P, Blouch MT, Nguyen F, Doubine S, Dutrillaux F, Alhenc-Gelas M, Martin-Toutain I, Bauters A, Ffrench P, de Maistre E, Grunebaum L, Mouton C, Huisse MG, Gouault-Heilmann M, Lucke V: Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. 2006 Sep 1;108(5):1492-6. Epub 2006 May 11.</span>
<span class="co">#&gt; 3                                                                                                                                                                                                                                                                      Lubenow N, Eichler P, Lietz T, Greinacher A: Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005 Nov;3(11):2428-36.</span>
<span class="co">#&gt; 4                                                                                                                                                                                                                                                                                Hosokawa N, Yamamoto S, Uehara Y, Hori M, Tsuchiya KS: Effect of thiazinotrienomycin B, an ansamycin antibiotic, on the function of epidermal growth factor receptor in human stomach tumor cells. J Antibiot (Tokyo). 1999 May;52(5):485-90.</span>
<span class="co">#&gt; 5                                                                                                                                                                                                                                                                                                                   Wakita H, Takigawa M: Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes. J Biol Chem. 1999 Dec 24;274(52):37285-91.</span>
<span class="co">#&gt; 6                                                                                                                                                                                                                                                                                Suwa T, Ueda M, Jinno H, Ozawa S, Kitagawa Y, Ando N, Kitajima M: Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells. Anticancer Res. 1999 Sep-Oct;19(5B):4161-5.</span>
<span class="co">#&gt;   parent_key</span>
<span class="co">#&gt; 1    DB00001</span>
<span class="co">#&gt; 2    DB00001</span>
<span class="co">#&gt; 3    DB00001</span>
<span class="co">#&gt; 4    DB00002</span>
<span class="co">#&gt; 5    DB00002</span>
<span class="co">#&gt; 6    DB00002</span></pre></body></html></div>
<div class="sourceCode" id="cb4"><html><body><pre class="r"><span class="fu"><a href="https://rdrr.io/r/utils/head.html">head</a></span>(<span class="kw pkg">dbdataset</span><span class="kw ns">::</span><span class="no">Drugs</span>)
<span class="co">#&gt;   primary_key                           other_keys           type    created</span>
<span class="co">#&gt; 1     DB00001                   BTD00024;BIOD00024        biotech 2005-06-13</span>
<span class="co">#&gt; 2     DB00002                   BTD00071;BIOD00071        biotech 2005-06-13</span>
<span class="co">#&gt; 3     DB00003                   BTD00001;BIOD00001        biotech 2005-06-13</span>
<span class="co">#&gt; 4     DB00004                   BTD00084;BIOD00084        biotech 2005-06-13</span>
<span class="co">#&gt; 5     DB00005                   BTD00052;BIOD00052        biotech 2005-06-13</span>
<span class="co">#&gt; 6     DB00006 BTD00076;EXPT03302;BIOD00076;DB02351 small molecule 2005-06-13</span>
<span class="co">#&gt;      updated                name</span>
<span class="co">#&gt; 1 2020-04-02           Lepirudin</span>
<span class="co">#&gt; 2 2020-04-22           Cetuximab</span>
<span class="co">#&gt; 3 2020-04-22        Dornase alfa</span>
<span class="co">#&gt; 4 2020-04-04 Denileukin diftitox</span>
<span class="co">#&gt; 5 2020-04-22          Etanercept</span>
<span class="co">#&gt; 6 2020-04-22         Bivalirudin</span>
<span class="co">#&gt;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      description</span>
<span class="co">#&gt; 1                                                                                                                                                                                                                                                                                                                                                                                                                               Lepirudin is identical to natural hirudin except for substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. It is produced via yeast cells. Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.</span>
<span class="co">#&gt; 2                                                                                                                                                                                                                                                           Cetuximab is an epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions. Cetuximab is marketed under the brand Erbitux® by Eli Lilly and Company. In the United States, a regimen of cetuximab costs approximately $30,790 for an eight-week course.</span>
<span class="co">#&gt; 3 Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections. Enzymatic breakdown of this extracellular DNA appears to reduce sputum viscosity and viscoelasticity.</span>
<span class="co">#&gt; 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.</span>
<span class="co">#&gt; 5                                                                                                                                                                                                                                                                  Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids.</span>
<span class="co">#&gt; 6                                                                                                                                                                                                                                                                                     Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.</span>
<span class="co">#&gt;    cas_number       unii average_mass monoisotopic_mass  state</span>
<span class="co">#&gt; 1 138068-37-8 Y43GF64R34           NA                NA liquid</span>
<span class="co">#&gt; 2 205923-56-4 PQX0D8J21J           NA                NA liquid</span>
<span class="co">#&gt; 3 143831-71-4 953A26OA1Y           NA                NA liquid</span>
<span class="co">#&gt; 4 173146-27-5 25E79B5CTM           NA                NA liquid</span>
<span class="co">#&gt; 5 185243-69-0 OP401G7OJC           NA                NA liquid</span>
<span class="co">#&gt; 6 128270-60-0 TN9BEX005G     2180.285          2178.986  solid</span>
<span class="co">#&gt;                                                                                                                                                                                                                synthesis_reference</span>
<span class="co">#&gt; 1                                                                                                                                                                                                                             &lt;NA&gt;</span>
<span class="co">#&gt; 2                                                                                                                                                                                                                             &lt;NA&gt;</span>
<span class="co">#&gt; 3                                                                                                                                                                                                                             &lt;NA&gt;</span>
<span class="co">#&gt; 4                                                                                                                                                                                                                             &lt;NA&gt;</span>
<span class="co">#&gt; 5                                             Timothy D. Osslund, Christi L. Clogston, Shon Lee Crampton, Randal B. Bass, "Crystals of etanercept and methods of making thereof." U.S. Patent US07276477, issued October 02, 2007.</span>
<span class="co">#&gt; 6 Avi Tovi, Chaim Eidelman, Shimon Shushan, Alon Hagi, Alexander Ivchenko, Gabriel-Marcus Butilca, Leah Bar-Oz, Tehila Gadi, Gil Zaovi, "Process for production of Bivalirudin." U.S. Patent US20070093423, issued April 26, 2007.</span>
<span class="co">#&gt;                                                                                                                                                                                                                                                                                                                                                                                                                                            indication</span>
<span class="co">#&gt; 1                                                                                                                                                                                                                                                                                                                                                                                               For the treatment of heparin-induced thrombocytopenia</span>
<span class="co">#&gt; 2                                                    Cetuximab, used in combination with irinotecan, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. Cetuximab administered as a single agent is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy.</span>
<span class="co">#&gt; 3                                                                                                                                                                                                                                                                                                                                                                                        Used as adjunct therapy in the treatment of cystic fibrosis.</span>
<span class="co">#&gt; 4                                                                                                                                                                                                                                                                                                                                                                                                          For treatment of cutaneous T-cell lymphoma</span>
<span class="co">#&gt; 5 Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more disease-modifying anti-rheumatic drugs. Etanercept is also used to improve psoriatic arthritis and ankylosing spondylitis.</span>
<span class="co">#&gt; 6                                                                                                                For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.</span>
<span class="co">#&gt;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               pharmacodynamics</span>
<span class="co">#&gt; 1                                                                                                                                                                                                                                                                                              Lepirudin is used to break up clots and to reduce thrombocytopenia. It binds to thrombin and prevents thrombus or clot formation. It is a highly potent, selective, and essentially irreversible inhibitor of thrombin and clot-bond thrombin. Lepirudin requires no cofactor for its anticoagulant action. Lepirudin is a recombinant form of hirudin, an endogenous anticoagulant found in medicinal leeches.</span>
<span class="co">#&gt; 2                                                         Used in the treatment of colorectal cancer, cetuximab binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor–alpha. Binding of cetuximab to the EGFr blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase secretion and reduced vascular endothelial growth factor production.</span>
<span class="co">#&gt; 3 Cystic fibrosis (CF) is a disease characterized by the retention of viscous purulent secretions in the airways. These thick secretions contribute both to reduced pulmonary function and to frequent pulmonary infection. Purulent pulmonary secretions of individuals with cystic fibrosis contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to these infections. Dornase alfa hydrolyzes the DNA in sputum of CF patients and reduces sputum viscosity and viscoelasticity. The enzyme does not appear to affect sputum in the absence of an inflammatory response to infection, nor does it affect the sputum of healthy individuals.</span>
<span class="co">#&gt; 4                                                                                                                              Denileukin diftitox (Ontak) directs the cytocidal action of diphtheria toxin to cells which express the IL-2 receptor. The human IL-2 receptor exists in three forms, low (CD25), intermediate (CD122/CD132) and high (CD25/CD122/CD132) affinity. Malignant cells expressing one or more of the subunits of the IL-2 receptor are found in certain leukemias and lymphomas including cutaneous T-cell lymphoma (CTCL). Ontak interacts with the high affinity IL-2 receptor on the cell surface and inhibits cellular protein synthesis, resulting in cell death within hours.</span>
<span class="co">#&gt; 5                                                                                                                                                                                                                                               Etanercept binds specifically to tumor necrosis factor (TNF) and thereby modulates biological processes that are induced or regulated by TNF. Such processes or molecules affected include the level of adhesion molecules expressed, as well as serum levels of cytokines and matrix metalloproteinase-3, also known as stromelysin. In animal models, etanarcept has been demonstrated to affect inflammation, such as in murine collagen-induced arthritis.</span>
<span class="co">#&gt; 6                                                                                                                                                                                                                                                                                                                                                                Bivalirudin mediates an inhibitory action on thrombin by directly and specifically binding to both the catalytic site and anion-binding exosite of circulating and clot-bound thrombin. The action of bivalirudin is reversible because thrombin will slowly cleave the thrombin-bivalirudin bond which recovers the active site of thrombin.</span>
<span class="co">#&gt;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             mechanism_of_action</span>
<span class="co">#&gt; 1                                                                                                                                                                                                                                                                                                                                                                                                                                     Lepirudin forms a stable non-covalent complex with alpha-thrombin, thereby abolishing its ability to cleave fibrinogen and initiate the clotting cascade. The inhibition of thrombin prevents the blood clotting cascade.</span>
<span class="co">#&gt; 2                                                                                                                                                                                                                                                                                                                                           Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.</span>
<span class="co">#&gt; 3                                         Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Extracellular DNA is a viscous anionic polymer and its breakdown appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction. Dornase alfa does not seem to have any effect on non-purulent sputum.</span>
<span class="co">#&gt; 4                                                                                                                                                                                                                                                                                                                                                                                                        Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.</span>
<span class="co">#&gt; 5 There are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75). The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55). Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation.\r\n\r\nTNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Increased levels of TNF are found in tissues and fluids of those with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (AS), and plaque psoriasis.</span>
<span class="co">#&gt; 6                                                                                                             Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.</span>
<span class="co">#&gt;                                                                                                                                                                                                                                                                                                metabolism</span>
<span class="co">#&gt; 1 Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. However, con-clusive data are not available. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.</span>
<span class="co">#&gt; 2                                                                                                                                                                                                                                                                                                    &lt;NA&gt;</span>
<span class="co">#&gt; 3                                                                                                                                                                              While no conclusive studies have yet been published, dornase alfa is expected to be metabolized by proteases in biofluids.</span>
<span class="co">#&gt; 4                                                                                                                                                                                                                                                                                                    &lt;NA&gt;</span>
<span class="co">#&gt; 5                                                                                                                                                                                                                                                                                                    &lt;NA&gt;</span>
<span class="co">#&gt; 6                                                                                                                                                                                                                                                                                80% proteolytic cleavage</span>
<span class="co">#&gt;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        absorption</span>
<span class="co">#&gt; 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Bioavailability is 100% following injection.</span>
<span class="co">#&gt; 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            &lt;NA&gt;</span>
<span class="co">#&gt; 3 Studies in rats and monkeys after inhalation of dornase alfa shows very little systemic absorption (less than 15% for rats and less than 2% for monkeys). The results were also witnessed in patients. Dornase alfa is also associated with very low accumulation with no serum concentration greater than 10ng/mL observed no matter the dose administered. Bioavailability: mean sputum concentrations of dornase alfa can be measured after 15 minutes. Onset is achieved within 3 to 7 days. Peak concentrations are achieved after 9 days.</span>
<span class="co">#&gt; 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            &lt;NA&gt;</span>
<span class="co">#&gt; 5                                                                                                                                                                                                                                                                                                                                                                                                                       Bioavailability following sub-Q administration is approximately 60%. Peak plasma concentrations achieved within 69 hours.</span>
<span class="co">#&gt; 6                                                                                                                                                                                                                                                                         Following intravenous administration, bivalirudin exhibits linear pharmacokinetics.  The mean steady state concentration is 12.3 +/- 1.7mcg/mL after administration of an intravenous bolus of 1mg/kg followd by a 2.5mg/kg/hr intravenous infusion given over 4 hours.</span>
<span class="co">#&gt;                                                                                                                                    half_life</span>
<span class="co">#&gt; 1                                                                                                                    Approximately 1.3 hours</span>
<span class="co">#&gt; 2                                                                        The mean half-life for Cetuximab is 114 hours (range 75-188 hours).</span>
<span class="co">#&gt; 3                                                                                                                                       &lt;NA&gt;</span>
<span class="co">#&gt; 4                                                                                                                                  70-80 min</span>
<span class="co">#&gt; 5                                                    102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults.</span>
<span class="co">#&gt; 6 * Normal renal function: 25 min (in normal conditions)\r\n* Creatinine clearance 10-29mL/min: 57min\r\n* Dialysis-dependant patients: 3.5h</span>
<span class="co">#&gt;                                                                          protein_binding</span>
<span class="co">#&gt; 1                                                                                   &lt;NA&gt;</span>
<span class="co">#&gt; 2                                                                                   &lt;NA&gt;</span>
<span class="co">#&gt; 3                                                                                   &lt;NA&gt;</span>
<span class="co">#&gt; 4                                                                                   &lt;NA&gt;</span>
<span class="co">#&gt; 5                                                                                   &lt;NA&gt;</span>
<span class="co">#&gt; 6 Other than thrombin and red blood cells, bivalirudin does not bind to plasma proteins.</span>
<span class="co">#&gt;                                                                                                                                                                                                                                         route_of_elimination</span>
<span class="co">#&gt; 1 Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.</span>
<span class="co">#&gt; 2                                                                                                                                                                                                                                                       &lt;NA&gt;</span>
<span class="co">#&gt; 3                                                                                                                                                                                                                                                       &lt;NA&gt;</span>
<span class="co">#&gt; 4                                                                                                                                                                                                                                                       &lt;NA&gt;</span>
<span class="co">#&gt; 5                                                                                                                                                                                                                                                       &lt;NA&gt;</span>
<span class="co">#&gt; 6                                                                                                                                                    Bivalirudin is cleared from plasma by a combination of renal mechanisms (20%) and proteolytic cleavage.</span>
<span class="co">#&gt;                                                                                                                                                                                                                                  volume_of_distribution</span>
<span class="co">#&gt; 1 * 12.2 L [Healthy young subjects (n = 18, age 18-60 years)]\r\n* 18.7 L [Healthy elderly subjects (n = 10, age 65-80 years)]\r\n* 18 L [Renally impaired patients (n = 16, creatinine clearance below 80 mL/min)]\r\n* 32.1 L [HIT patients (n = 73)]</span>
<span class="co">#&gt; 2                                                                                                                                                                   appeared to be independent of dose and approximated the vascular space of 2-3 L/m2.</span>
<span class="co">#&gt; 3                                                                                         In studies in rats and monkeys, the initial volume of distribution is similar to the serum volume. Concentrations in sputum decline rapidly after inhalation.</span>
<span class="co">#&gt; 4                                                                                                                                                                                                                                   * 0.06 to 0.09 L/kg</span>
<span class="co">#&gt; 5                                                                                                                                                                                                                                                  &lt;NA&gt;</span>
<span class="co">#&gt; 6                                                                                                                                                                                                                                               0.2L/kg</span>
<span class="co">#&gt;                                                                                                                                                                                                                                                                                                                clearance</span>
<span class="co">#&gt; 1                                                                                                                                                          * 164 ml/min [Healthy 18-60 yrs]\r\n* 139 ml/min [Healthy 65-80 yrs]\r\n* 61 ml/min [renal impaired]\r\n* 114 ml/min [HIT (Heparin-induced thrombocytopenia)]</span>
<span class="co">#&gt; 2                                                                                                                                                                                                                                                  Female patients had 25% lower intrinsic clearance than male patients.</span>
<span class="co">#&gt; 3 Studies in rats indicate that, following aerosol administration, the disappearance half-life of dornase alfa from the lungs is 11 hours. In humans, sputum DNase levels declined below half of those detected immediately post-administration within 2 hours but effects on sputum rheology persisted beyond 12 hours.</span>
<span class="co">#&gt; 4                                                                                                                                                                                                                                                                                       * 0.6 - 2.0 mL/min/kg [Lymphoma]</span>
<span class="co">#&gt; 5                                                                                                                                                                                                                                                                                       * 160 +/- 80 mL/hr [RA patients]</span>
<span class="co">#&gt; 6                                                                                                * 3.4 mL/min/kg [Normal renal function]\r\n* 3.4 mL/min/kg [mild renal function]\r\n* 2.7 mL/min/kg [moderate renal function]\r\n* 2.8 mL/min/kg [severe renal function]\r\n* 1 mL/min/kg [Dialysis-dependent patients]</span>
<span class="co">#&gt;     international_brands</span>
<span class="co">#&gt; 1                   &lt;NA&gt;</span>
<span class="co">#&gt; 2                   &lt;NA&gt;</span>
<span class="co">#&gt; 3 ViscozymeRoche (Chile)</span>
<span class="co">#&gt; 4                   &lt;NA&gt;</span>
<span class="co">#&gt; 5         DavictrelTunex</span>
<span class="co">#&gt; 6          AngioxHirulog</span>
<span class="co">#&gt;                                                                 fda_label</span>
<span class="co">#&gt; 1 //s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00001.pdf?1265924858</span>
<span class="co">#&gt; 2 //s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00002.pdf?1265922813</span>
<span class="co">#&gt; 3 //s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00003.pdf?1410715221</span>
<span class="co">#&gt; 4 //s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00004.pdf?1265922800</span>
<span class="co">#&gt; 5                                                                    &lt;NA&gt;</span>
<span class="co">#&gt; 6 //s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00006.pdf?1265922803</span>
<span class="co">#&gt;                                                                msds</span>
<span class="co">#&gt; 1 //s3-us-west-2.amazonaws.com/drugbank/msds/DB00001.pdf?1368416245</span>
<span class="co">#&gt; 2 //s3-us-west-2.amazonaws.com/drugbank/msds/DB00002.pdf?1458412933</span>
<span class="co">#&gt; 3 //s3-us-west-2.amazonaws.com/drugbank/msds/DB00003.pdf?1410714694</span>
<span class="co">#&gt; 4                                                              &lt;NA&gt;</span>
<span class="co">#&gt; 5                                                              &lt;NA&gt;</span>
<span class="co">#&gt; 6                                                              &lt;NA&gt;</span>
<span class="co">#&gt;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              toxicity</span>
<span class="co">#&gt; 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              In case of overdose (eg, suggested by excessively high aPTT values) the risk of bleeding is increased.</span>
<span class="co">#&gt; 2 Pulmonary Toxicity\r\n\r\nInterstitial lung disease (ILD) was reported in 3 of 633 (&lt;0.5%) patients with advanced colorectal cancer receiving cetuximab. Interstitial pneumonitis with non-cardiogenic pulmonary edema resulting in death was reported in one case. Two patients had pre-existing fibrotic lung disease and experienced an acute exacerbation of their disease while receiving cetuximab in combination with irinotecan. In the clinical investigational program, an additional case of interstitial pneumonitis was reported in a patient with head and neck cancer treated with cetuximab and cisplatin. The onset of symptoms occurred between the fourth and eleventh doses of treatment in all reported cases.</span>
<span class="co">#&gt; 3                                                                                                                                                                                                          Adverse reactions occur at a frequency of &lt; 1/1000 and are usually mild and transient in nature. Reported adverse effects include chest pain (pleuritic/non-cardiac), fever, dyspepsia, voice alteration (hoarseness), pharyngitis, dyspnea, laryngitis, rhinitis, decreased lung function, rash, urticaria, and conjunctivitis. There is no evidence of carcinogenic or mutagenic properties. The safety of dornase alfa has not been studied in pregnant women, nursing women and children under the age of 5 years old.</span>
<span class="co">#&gt; 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                &lt;NA&gt;</span>
<span class="co">#&gt; 5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                &lt;NA&gt;</span>
<span class="co">#&gt; 6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Based on a study by Gleason et al., the no-observed-adverse-effect level (NOAEL) for bivalirudin, administered to rats via intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h.</span></pre></body></html></div>
<div class="sourceCode" id="cb5"><html><body><pre class="r"><span class="fu"><a href="https://rdrr.io/r/utils/head.html">head</a></span>(<span class="kw pkg">dbdataset</span><span class="kw ns">::</span><span class="no">Drugs_Pathway_Drug</span>)
<span class="co">#&gt;   drugbank-id          name parent_key</span>
<span class="co">#&gt; 1     DB00001     Lepirudin SMP0000278</span>
<span class="co">#&gt; 2     DB01022 Phylloquinone SMP0000278</span>
<span class="co">#&gt; 3     DB01373       Calcium SMP0000278</span>
<span class="co">#&gt; 4     DB00002     Cetuximab SMP0000474</span>
<span class="co">#&gt; 5     DB00006   Bivalirudin SMP0000277</span>
<span class="co">#&gt; 6     DB01022 Phylloquinone SMP0000277</span></pre></body></html></div>
<p>The 74 object names are listed in the next section and can be used immediately as any regular R dataframe.</p>
</div>
<div id="package-version" class="section level3">
<h3 class="hasAnchor">
<a href="#package-version" class="anchor"></a>Package Version</h3>
<p>The package version will always be the same as the <strong>DrugBank</strong> database used.</p>
</div>
<div id="naming-convention" class="section level3">
<h3 class="hasAnchor">
<a href="#naming-convention" class="anchor"></a>Naming Convention</h3>
<p>Each data frame is named based on its position in DrugBank’s data hierarchy. For example:</p>
<ul>
<li>
<code>Drugs</code>: is the master data frame at the root of the hierarchy that contains the list of all drugs in DrugBank.</li>
<li>
<code>Enzymes_Drug</code>: is the data frame containing the <em>enzymes</em> info pertaining to the drugs in the <code>Drugs</code> data frame. In other words,</li>
<li>
<code>Enzymes:</code> is a child of <code>Drug</code> in the hierarchy (i.e. Drug –&gt; Enzymes).</li>
<li>
<code>Enzymes_Pathway_Drug</code>: is the data frame containing the <em>enzymes</em> info pertaining to the <em>pathways</em> that the drugs in <code>Drugs</code> are involved in (i.e. Drug –&gt; Pathways –&gt; Enzymes).</li>
</ul>
</div>
</div>
<div id="dataset-contents" class="section level2">
<h2 class="hasAnchor">
<a href="#dataset-contents" class="anchor"></a>Dataset Contents</h2>
<p>The following are the datasets in our package</p>
<pre><code>#&gt; Loading package: dbdataset</code></pre>
<div id="htmlwidget-feb4cc4cc8c2c8482448" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-feb4cc4cc8c2c8482448">{"x":{"filter":"none","data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75"],["AHFS_Codes_Drug","ATC_Codes_Drug","Actions_Carrier_Drug","Actions_Enzyme_Drug","Actions_Target_Drug","Actions_Transporter_Drug","Affected_Organisms_Drug","Articles_Carrier_Drug","Articles_Drug","Articles_Enzyme_Drug","Articles_Target_Drug","Articles_Transporter_Drug","Books_Drug","Calculated_Properties_Drug","Carriers_Drug","Categories_Drug","Classifications_Drug","Dosages_Drug","Drugs","Drugs_Pathway_Drug","Enzymes_Drug","Enzymes_Pathway_Drug","Enzymes_Reactions_Drug","Experimental_Properties_Drug","External_Identifiers_Drug","External_Identifiers_Polypeptide_Carrier_Drug","External_Identifiers_Polypeptide_Enzyme_Drug","External_Identifiers_Polypeptide_Target_Drug","External_Identifiers_Transporter_Drug","External_Links_Drug","Food_Interactions_Drug","GO_Classifiers_Polypeptide_Carrier_Drug","GO_Classifiers_Polypeptide_Target_Drug","GO_Classifiers_Polypeptide_Transporter_Drug","GO_Classifiers_Polypeptides_Enzyme_Drug","Groups_Drug","Interactions_Drug","International_Brands_Drug","Links_Carrier_Drug","Links_Drug","Links_Enzyme_Drug","Links_Target_Drug","Links_Transporter_Drug","Manufacturers_Drug","Mixtures_Drug","PDB_Entries_Drug","PFAMS_Polypeptid_Transporter_Drug","PFAMS_Polypeptide_Carrier_Drug","PFAMS_Polypeptide_Target_Drug","PFAMS_Polypeptides_Enzyme_Drug","Packagers_Drug","Patents_Drug","Pathways_Drug","Polypeptide_Target_Drug","Polypeptides_Carrier_Drug","Polypeptides_Enzyme_Drug","Polypeptides_Transporter_Drug","Prices_Drug","Products_Drug","Reactions_Drug","SNP_Adverse_Drug_Reactions_Drug","SNP_Effects_Drug","Salts_Drug","Sequences_Drug","Synonyms_Drug","Synonyms_Polypeptide_Carrier_Drug","Synonyms_Polypeptide_Target_Drug","Synonyms_Polypeptide_Transporter_Drug","Synonyms_Polypeptides_Enzyme_Drug","Targets_Drug","Textbooks_Carrier_Drug","Textbooks_Enzyme_Drug","Textbooks_Target_Drug","Textbooks_Transporter_Drug","Transporters_Drug"],["1757x2","4973x10","109x2","640x2","3342x2","332x2","3135x2","615x4","12783x4","5536x4","22046x4","2193x4","433x4","275601x4","785x6","86211x3","10047x9","40004x4","13563x27","7438x3","5084x8","15198x2","222x3","6868x4","82849x3","418x3","2225x3","21629x3","1235x3","3088x3","1336x2","1806x3","76872x3","4520x3","7859x3","16110x2","2669764x4","8535x3","103x4","4136x4","806x4","642x4","228x4","5971x2","181299x3","209870x2","399x3","132x3","8294x3","665x3","20499x3","8501x6","3780x4","4828x20","82x20","436x20","261x20","11807x5","339945x19","3209x6","113x9","211x9","2313x8","360x3","28304x4","80x2","4320x2","252x2","421x2","19282x6","21x4","78x4","112x4","12x4","2983x6"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Item<\/th>\n      <th>dim<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}]}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="dataset-hierarchy" class="section level2">
<h2 class="hasAnchor">
<a href="#dataset-hierarchy" class="anchor"></a>Dataset Hierarchy</h2>
<p>The following illustrates how the datasets are related to each other:</p>
<div id="htmlwidget-18e9da67bf0a15d6148a" style="width:960px;height:960px;" class="radialNetwork html-widget"></div>
<script type="application/json" data-for="htmlwidget-18e9da67bf0a15d6148a">{"x":{"root":{"name":"Drugs","children":[{"name":"Groups"},{"name":"Names"},{"name":"References","children":[{"name":"Articles"},{"name":"Books"},{"name":"Links"}]},{"name":"Classification"},{"name":"Calculated Properties"},{"name":"Synonyms"},{"name":"Products"},{"name":"Mixtures"},{"name":"Packagers"},{"name":"Manufacturers"},{"name":"Prices"},{"name":"Categories"},{"name":"Affected Organisms"},{"name":"Dosages"},{"name":"ATC"},{"name":"AHFS"},{"name":"PDB Entries"},{"name":"Patents"},{"name":"international_brands"},{"name":"salts"},{"name":"Interactions","children":[{"name":"Food"},{"name":"Drugs"}]},{"name":"Sequences"},{"name":"Experimental Properties"},{"name":"External Identifiers"},{"name":"External Links"},{"name":"Pathways","children":[{"name":"Drugs"},{"name":"Enzymes"}]},{"name":"Reactions","children":[{"name":"Reactions Enzymes"}]},{"name":"SNP Effects"},{"name":"SNP Adverse DRs"},{"name":"Targets","children":[{"name":"Actions"},{"name":"References","children":[{"name":"Articles"},{"name":"Books"},{"name":"Links"}]},{"name":"Polypeptides","children":[{"name":"External Identifiers"},{"name":"GO Classifiers"},{"name":"PFAMS"},{"name":"Synonyms"}]}]},{"name":"Enzymes","children":[{"name":"Actions"},{"name":"References","children":[{"name":"Articles"},{"name":"Books"},{"name":"Links"}]},{"name":"Polypeptides","children":[{"name":"External Identifiers"},{"name":"GO Classifiers"},{"name":"PFAMS"},{"name":"Synonyms"}]}]},{"name":"Carriers","children":[{"name":"Actions"},{"name":"References","children":[{"name":"Articles"},{"name":"Books"},{"name":"Links"}]},{"name":"Polypeptides","children":[{"name":"External Identifiers"},{"name":"GO Classifiers"},{"name":"PFAMS"},{"name":"Synonyms"}]}]},{"name":"Transporters","children":[{"name":"Actions"},{"name":"References","children":[{"name":"Articles"},{"name":"Books"},{"name":"Links"}]},{"name":"Polypeptides","children":[{"name":"External Identifiers"},{"name":"GO Classifiers"},{"name":"PFAMS"},{"name":"Synonyms"}]}]}]},"options":{"height":null,"width":null,"fontSize":10,"fontFamily":"serif","linkColour":"#ccc","nodeColour":"#fff","nodeStroke":"steelblue","textColour":"#111","margin":{"top":null,"right":null,"bottom":null,"left":null},"opacity":0.9}},"evals":[],"jsHooks":[]}</script>
</div>
  </div>

  <div class="col-md-3 hidden-xs hidden-sm" id="pkgdown-sidebar">

        <nav id="toc" data-toggle="toc"><h2 data-toc-skip>Contents</h2>
    </nav>
</div>

</div>



      <footer><div class="copyright">
  <p>Developed by Mohammed Ali.</p>
</div>

<div class="pkgdown">
  <p>Site built with <a href="https://pkgdown.r-lib.org/">pkgdown</a> 1.5.1.</p>
</div>

      </footer>
</div>

  


  </body>
</html>
